Joshua Fitch, Senior Editor

A new study aimed to determine mental health resilience in preterm-born children and identify modifiable factors associated with resilience.

According to research from 2021 to 2023, approximately 50% of adolescents who vaped had tried to quit in the last 12 months.

The nitric oxide–releasing topical is the first prescription medication approved for at-home treatment of molluscum contagiosum.

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

A week into July 2025, the total reported cases in the United States have surpassed the peak of 1274 cases recorded for all 2019.

Six medical societies, including the American Academy of Pediatrics, are suing the HHS and its Secretary to "defend vaccine policy."

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The American Academy of Pediatrics warns families to avoid home fireworks and offers safer alternatives to prevent injuries, especially in young children.

Additionally, long sleep duration could be associated with increased odds of being reliably symptomatic at 4 weeks.

Data from the study suggest caretakers of CPP patients be vigilant for psychiatric symptoms to begin care at an early stage.

The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.

The updated labeling includes a new contraindication for patients with prior or active hepatic events.

MNV-201 is being evaluated in phase 2 clinical trials for treatment of the ultra-rare, life-threatening mitochondrial disorder affecting children.

The total number of pediatric mental health hospitalizations declined in 2022, the first time observed since 2009.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

The American Academy of Pediatrics will continue to hold its own childhood vaccine schedule, as it has since the 1930s.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Lenacapavir is the first twice-yearly option available in the US for those who need or want PrEP, according to Gilead Sciences.

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

The federal agency has assigned a target action date of January 31, 2026, for a decision.

Garadacimab-gxii is the only treatment to target factor Xlla for prophylactic use to prevent attacks of HAE in patients aged 12 years and older.

Though the decision will not meet the June 17, 2025, target date, the federal agency anticipates a decision within approximately 4 weeks.

The approval for ustekinumab-stba now offers all dosage forms to the reference product, ustekinumab, and is indicated for patients aged 6 to 17 years.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.